Related Experiment Video
Updated: Jun 6, 2026
08:13
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
Published on: March 22, 2016
Denosumab: What's new?
Cesar E Bogado1, Maria Belen Zanchetta, Juan A Boailchuk
1Instituto de Investigaciones Metabolicas, Libertad 836, C1012AAR, Buenos Aires, Argentina. bogadoc@idim.com.ar
Current Osteoporosis Reports
|December 7, 2010
Summary
Denosumab, a novel osteoporosis treatment, significantly reduces fracture risk in postmenopausal women by inhibiting osteoclast activity. This fully human monoclonal antibody offers a new therapeutic option with an acceptable side effect profile.
Area of Science:
- Immunology
- Bone Biology
- Pharmacology
Background:
- Osteoporosis is a significant public health concern, particularly in postmenopausal women.
- Current treatments aim to reduce bone resorption and increase bone mineral density.
- There is a need for effective therapeutic options with favorable safety profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of denosumab in treating postmenopausal osteoporosis.
- To assess the impact of denosumab on bone resorption and bone mineral density.
- To determine the risk reduction of fractures associated with denosumab treatment.
Main Methods:
- Denosumab is a fully human monoclonal antibody targeting the RANKL/RANK pathway.
- Clinical studies assessed denosumab's effect on osteoclast formation, function, and survival.
- Data analyzed fracture risk reduction, bone mineral density changes, and side effect rates.
Main Results:
- Denosumab significantly decreases bone resorption and increases bone mineral density.
- Treatment with denosumab 60 mg twice yearly reduces the risk of vertebral, hip, and nonvertebral fractures.
- The drug demonstrates an acceptable rate of side effects in clinical studies.
Conclusions:
- Denosumab represents a new therapeutic choice for postmenopausal osteoporosis in high-risk patients.
- Its mechanism of action effectively targets osteoclast-mediated bone loss.
- Ongoing trials will further elucidate its potential in other indications and immunomodulatory effects.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...